Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

David Moher, Kenneth F. Schulz, Douglas G. Altman · The Lancet · 2001 · 5.4K citations · Full text

Public Health, Biostatistics, Health Sciences +12

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text

Medicine, Hematology, Oncology +14

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink et al. · Blood · 2015 · 700 citations · Full text

Life Sciences, Immunology, Oncology +8

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

Constantine S. Tam, Susan O’Brien, William G. Wierda et al. · Blood · 2008 · 689 citations · Full text

Medicine, Oncology, Pharmacotherapy +16